Acute On Chronic Liver Failure Pipeline Summary

DelveInsight’s, “Acute On Chronic Liver Failure Pipeline Insight, 2026” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Acute On Chronic Liver Failure pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Acute On Chronic Liver Failure: Understanding

Acute On Chronic Liver Failure: Overview

Acute on Chronic Liver Failure (ACLF) is a clinical syndrome of sudden hepatic decompensation observed in patients with pre-existing chronic liver disease and associated with one or more extrahepatic organ failures and increased mortality. Regardless of the etiology of chronic liver injury, when a clinician follows the natural history of liver injury, the initial uncomplicated chronic liver disease leads to cirrhosis and, later, the decompensation of liver function with ascites, jaundice, portal hypertension with variceal bleeding, and hepatic encephalopathy. There are two types of the indication. Type-A ACLF is an acute worsening of liver function in a patient with chronic liver disease. Type-B ACLF is when this acute decompensation occurs in patients with cirrhosis, while type-C ACLF is acute worsening of liver function in decompensated cirrhotics.

Symptoms of ACLF reflect sudden hepatic decompensation along with systemic involvement. Patients commonly present with jaundice, hepatic encephalopathy (ranging from confusion to coma), and coagulopathy leading to bleeding tendencies. Other frequent features include ascites, acute kidney injury, and signs of systemic inflammation or infection. As the condition progresses, multiple organ dysfunction may develop, manifesting as respiratory failure, circulatory instability, and worsening neurological status. Overall, ACLF is characterized by a combination of liver-related symptoms and extrahepatic organ failures, contributing to its high short-term mortality.

ACLF commonly occurs in patients with chronic liver disease, particularly cirrhosis, and is frequently seen among those hospitalized with acute decompensation.

ACLF is associated with high short-term mortality, typically ranging from 30% to 50%, increasing with the number of organ failures.

Approximately one-third of patients admitted with decompensated cirrhosis develop ACLF, with higher rates observed in regions like South Asia.

The pathophysiology is based on the understanding that an acute precipitating event in a patient with a chronic liver condition that injures hepatocytes leads to the accumulation of a cascade of inflammatory cytokines and results in further hepatic injury in the presence of failure of hepatocyte regeneration. The resulting compromise in immune function and liver decompensation leads to further susceptibility to infections, multi-organ failure, and death. Systemic inflammation with elevated leukocytosis, cytokines, and chemokines (including IL-6 and IL-8) are observed in patients with ACLF. This is usually absent in cirrhotic patients with ACLF.

The diagnosis of ACLF is made in patients with acute decompensation of liver cirrhosis with organ failure. Organ failure is defined by the Chronic Liver Failure – Sequential Organ Failure Assessment (CLIF-SOFA) score which is a modification of the SOFA score.

There is currently no specific therapy for ACLF. The main principles of treatment are to diagnose and treat precipitating events and provide supportive therapy. Organ support in an intensive care unit, with care overseen by physicians who are experts in liver disease management, may be of benefit for patients with life-threatening, single- or multiple-organ failure who have not responded to standard therapy. The 1-year survival rates after liver transplantation among patients with ACLF with one or two organ failures do not differ significantly from patients without organ failures. In patients with three or more organ failures, the survival post-transplantation approaches 80% as compared with survival rates of less than 20% among patients who do not undergo liver transplantation. In addition to supportive care, management of ACLF involves early recognition and aggressive treatment of complications such as infections, renal dysfunction, and hepatic encephalopathy to prevent further deterioration. Close monitoring and a multidisciplinary approach are essential to stabilize patients.

"Acute On Chronic Liver Failure Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute on Chronic Liver Failure pipeline landscape is provided which includes the disease overview and Acute on Chronic Liver Failure treatment guidelines. The assessment part of the report embraces, in depth Acute on Chronic Liver Failure commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute On Chronic Liver Failure collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Acute on Chronic Liver Failure R&D. The therapies under development are focused on novel approaches to treat/improve Acute on Chronic Liver Failure.

Acute On Chronic Liver Failure Emerging Drugs Chapters

This segment of the Acute On Chronic Liver Failure report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Acute On Chronic Liver Failure Emerging Drugs

G1090N: GENFIT

G1090N (a reformulated nitazoxanide) is an investigational drug for Acute-on-Chronic Liver Failure (ACLF). It is based on nitazoxanide (NTZ), a compound with known antiviral and anti-inflammatory properties, but reformulated to improve its effectiveness in patients with severe liver and renal impairment. G1090N exerts its therapeutic effect primarily through modulation of systemic inflammation and immune responses. Its active metabolite, tizoxanide, has been shown to inhibit pro-inflammatory signaling pathways in circulating immune cells, including suppression of lipopolysaccharide (LPS)-induced cytokines such as IL-6 and TNF-α, thereby reducing excessive inflammatory responses. The drug is in the Phase I stage of its development for the treatment of Acute on Chronic Liver Failure.

Further product details are provided in the report...

Acute On Chronic Liver Failure: Therapeutic Assessment

This segment of the report provides insights about the different Acute on Chronic Liver Failure drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Acute On Chronic Liver Failure

There are approx. 3+ key companies which are developing the therapies for Acute on Chronic Liver Failure. The companies which have their Acute on Chronic Liver Failure drug candidates in the most advanced stage, i.e. Phase III include, GENFIT.

Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Route of Administration

Acute on Chronic Liver Failure pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Molecule Type

Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acute On Chronic Liver Failure: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Acute on Chronic Liver Failure therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute on Chronic Liver Failure drugs.

Acute On Chronic Liver Failure Report Insights

Acute On Chronic Liver Failure Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs

Acute On Chronic Liver Failure Report Assessment

Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
How many companies are developing Acute on Chronic Liver Failure drugs?
How many Acute on Chronic Liver Failure drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute on Chronic Liver Failure?
What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Acute on Chronic Liver Failure therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Acute on Chronic Liver Failure and their status?
What are the key designations that have been granted to the emerging drugs?

Key Players